科伦药业：公司产品拟中标第十一批全国药品集中采购

Core Viewpoint - The company and its subsidiaries participated in the 11th national centralized procurement organized by the National Organization for Drug Procurement, with several products expected to win bids [1] Group 1: Products and Sales Revenue - The products expected to win bids include Malate Avacopan Tablets, Acalabrutinib Ethanolamine Tablets, Compound Sodium Acetate Ringer's Injection, and Agomelatine Tablets [1] - The projected sales revenue for Acalabrutinib Ethanolamine Tablets in 2024 is 19.94 million yuan [1] - The sales revenue for Compound Sodium Acetate Ringer's Injection is 17.73 million yuan for 2023 and 7.93 million yuan for 2024 [1]